Gastrointestinal Stromal Cancer clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
open to eligible people ages 18 years and up
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib as current or prior therapy, or are treatment naive.
Orange, California and other locations
Our lead scientists for Gastrointestinal Stromal Cancer research studies include Warren Chow.
Last updated: